source
- Merck and Moderna’s mRNA melanoma vaccine cuts recurrence risk by 42% in Phase 3 trialA Phase 3 study of a personalized mRNA vaccine for melanoma, developed by Merck and Moderna, showed a substantial improvement in patient outcomes. Patients receiving the vaccine together with Merc…
- Akeso reports survival benefit for ivonescimab in China-only biliary tract cancer trial, likening results to KeytrudaAkeso announced new data from a late‑stage study of its PD‑1×VEGF bispecific antibody ivonescimab in patients with biliary tract cancer enrolled only in China. The trial showed an improvement in o…